Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) Targeting Tumor-Specific Neoantigens, With in Vivo CD40 Activation and PD-1 Blockade, for Patients With Incurable Cancers (2020000584)

Summary

The purpose of this phase I/IIB trial is to evaluate the safety and tolerability of T-cell receptor gene-engineered T cells (TCR-T) in combination with pembrolizumab and CDX-1140 in patients with solid tumors, including pancreatic cancer.

General Information

NCT#: NCT04520711
Study ID: 2020000584
Trial Phase: Phase I

Trial Sponsor: Providence Portland Medical Center
Therapies Used in This Trial: CDX-1140, Pembrolizumab, TCR-transduced T cells

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search